{"id":2577,"date":"2021-01-27T03:57:09","date_gmt":"2021-01-27T01:57:09","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=2577"},"modified":"2021-01-27T03:57:11","modified_gmt":"2021-01-27T01:57:11","slug":"primer-tratamiento-oral-para-nefritis-lupica","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=2577","title":{"rendered":"Primer tratamiento oral para nefritis l\u00fapica"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">El primer tratamiento oral aprobado por la FDA (la Agencia de medicamentos de EEUU) para la nefritis l\u00fapica representa un hecho importante para las personas que viven con enfermedad renal relacionada con el lupus,  que es una de las principales causas de discapacidad y mortalidad en el lupus.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Por segunda vez en menos de dos meses, la Administraci\u00f3n de Drogas y Alimentos de EE. UU. (FDA) aprob\u00f3 un nuevo medicamento para tratar a adultos con\u00a0nefritis l\u00fapica \u00a0en combinaci\u00f3n con un r\u00e9gimen de terapia inmunosupresora de base.\u00a0Aurinia Pharmaceuticals podr\u00e1 comercializar\u00a0<a href=\"https:\/\/www.lupus.org\/resources\/lupkynis-voclosporin-what-you-need-to-know\">Lupkynis &#x2122; (voclosporina)<\/a>\u00a0, una terapia oral que bloquea la calcineurina, prote\u00edna del sistema inmunol\u00f3gico.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lupkynis es un f\u00e1rmaco inmunosupresor que se une a la enzima calcineurina, una prote\u00edna de se\u00f1alizaci\u00f3n que activa las c\u00e9lulas T.\u00a0Al unirse a la calcineurina, Lupkynis bloquea las c\u00e9lulas T para que no provoquen una respuesta autoinmune, lo que reduce la inflamaci\u00f3n en los ri\u00f1ones.<\/p>\n\n\n\n<p class=\"has-vivid-purple-color has-text-color has-medium-font-size wp-block-paragraph\">Stevan W. Gibson, presidente y director ejecutivo de Lupus Foundation of America dijo<em> \u201cDurante mucho tiempo, no hubo tratamientos aprobados para esta complicaci\u00f3n del lupus potencialmente discapacitante y potencialmente mortal.\u00a0Estamos encantados de que los m\u00e9dicos tengan ahora una segunda opci\u00f3n nueva para tratar la nefritis l\u00fapica, que afecta hasta al 60% de las personas con lupus \u00ab.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La Dra Karen H. Costenbader, MPH, directora del Programa de Lupus en Brigham and Women&#8217;s Hospital en Boston y presidenta del Consejo Asesor M\u00e9dico-Cient\u00edfico de la Fundaci\u00f3n Lupus de Am\u00e9rica, elogi\u00f3 a las personas con lupus que participan en estudios de posibles nuevos tratamientos.<em>\u00a0\u00abSin estos voluntarios dedicados a los ensayos cl\u00ednicos, no ser\u00eda posible asegurar la aprobaci\u00f3n de nuevos tratamientos para el lupus que salvan y mejoran la vida. Y con m\u00e1s ensayos cl\u00ednicos sobre el lupus en varias etapas de planificaci\u00f3n, la participaci\u00f3n de los voluntarios seguir\u00e1 siendo vital para asegurar el desarrollo de m\u00e1s terapias para el lupus \u00ab.<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-style-rounded\"><a href=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\"><img loading=\"lazy\" decoding=\"async\" width=\"277\" height=\"182\" src=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\" alt=\"\" class=\"wp-image-2580\"\/><\/a><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">M\u00e1s informaci\u00f3n en <a href=\"https:\/\/www.lupus.org\/news\/lupus-foundation-of-america-aurinia-pharmaceuticals-fda-approval-lupkynis\">Lupus.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El primer tratamiento oral aprobado por la FDA (la Agencia de medicamentos de EEUU) para la nefritis l\u00fapica representa un hecho importante para las personas que viven con enfermedad renal relacionada con el lupus, que es una de las principales causas de discapacidad y mortalidad en el lupus. Por segunda vez en menos de dos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2580,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[6,5,79],"tags":[74,54,80,16],"class_list":["post-2577","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investigacion","category-lupus-internacional","category-medicacion","tag-lupus","tag-lupus-foundation-of-america","tag-nefritis","tag-tratamientos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=2577\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"El primer tratamiento oral aprobado por la FDA (la Agencia de medicamentos de EEUU) para la nefritis l\u00fapica representa un hecho importante para las personas que viven con enfermedad renal relacionada con el lupus, que es una de las principales causas de discapacidad y mortalidad en el lupus. Por segunda vez en menos de dos [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=2577\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2021-01-27T01:57:09+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2021-01-27T01:57:11+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\" \/>\r\n\t<meta property=\"og:image:width\" content=\"277\" \/>\r\n\t<meta property=\"og:image:height\" content=\"182\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"Primer tratamiento oral para nefritis l\u00fapica\",\"datePublished\":\"2021-01-27T01:57:09+00:00\",\"dateModified\":\"2021-01-27T01:57:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\",\"keywords\":[\"lupus\",\"Lupus Foundation of America\",\"nefritis\",\"Tratamientos\"],\"articleSection\":[\"Investigaci\u00f3n\",\"Lupus Internacional\",\"medicaci\u00f3n\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2577#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577\",\"url\":\"https:\/\/lupusgalicia.org\/?p=2577\",\"name\":\"Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\",\"datePublished\":\"2021-01-27T01:57:09+00:00\",\"dateModified\":\"2021-01-27T01:57:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=2577\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#primaryimage\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png\",\"width\":277,\"height\":182},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=2577#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Primer tratamiento oral para nefritis l\u00fapica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=2577","og_locale":"es_ES","og_type":"article","og_title":"Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus","og_description":"El primer tratamiento oral aprobado por la FDA (la Agencia de medicamentos de EEUU) para la nefritis l\u00fapica representa un hecho importante para las personas que viven con enfermedad renal relacionada con el lupus, que es una de las principales causas de discapacidad y mortalidad en el lupus. Por segunda vez en menos de dos [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=2577","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2021-01-27T01:57:09+00:00","article_modified_time":"2021-01-27T01:57:11+00:00","og_image":[{"width":277,"height":182,"url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png","type":"image\/png"}],"author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=2577#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=2577"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"Primer tratamiento oral para nefritis l\u00fapica","datePublished":"2021-01-27T01:57:09+00:00","dateModified":"2021-01-27T01:57:11+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2577"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2577#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png","keywords":["lupus","Lupus Foundation of America","nefritis","Tratamientos"],"articleSection":["Investigaci\u00f3n","Lupus Internacional","medicaci\u00f3n"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=2577#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=2577","url":"https:\/\/lupusgalicia.org\/?p=2577","name":"Primer tratamiento oral para nefritis l\u00fapica - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=2577#primaryimage"},"image":{"@id":"https:\/\/lupusgalicia.org\/?p=2577#primaryimage"},"thumbnailUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png","datePublished":"2021-01-27T01:57:09+00:00","dateModified":"2021-01-27T01:57:11+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=2577#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=2577"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/?p=2577#primaryimage","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2021\/01\/nefri.png","width":277,"height":182},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=2577#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"Primer tratamiento oral para nefritis l\u00fapica"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2577"}],"version-history":[{"count":2,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2577\/revisions"}],"predecessor-version":[{"id":2581,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/2577\/revisions\/2581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/media\/2580"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}